LENZ THERAPEUTICS, INC. Unrealized Gain (Loss) on Investments
LENZ THERAPEUTICS, INC. (LENZ) reported Unrealized Gain (Loss) on Investments of $1.05 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2023-12-31 was $95.00K.
- LENZ THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2023-09-30 was $176.00K.
- LENZ THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2023-06-30 was $198.00K.
- LENZ THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2023-03-31 was $579.00K.
- LENZ THERAPEUTICS, INC. unrealized gain (loss) on investments for fiscal 2023 was $1.05M.
- LENZ THERAPEUTICS, INC. unrealized gain (loss) on investments for fiscal 2022 was -$1.05M.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2023-12-31 | $95.00K derived: 10-K 12 month − 3 quarters · filed 2024-02-27 | $271.00K derived: sum of 2 quarters · filed 2024-02-27 | $469.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.05M 10-K · filed 2024-02-27 |
| 2023-09-30 | $176.00K 10-Q · filed 2023-11-13 | $374.00K derived: sum of 2 quarters · filed 2023-11-13 | $953.00K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2023-06-30 | $198.00K 10-Q · filed 2023-11-13 | $777.00K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2023-03-31 | $579.00K 10-Q · filed 2023-11-13 | |||
| 2022-12-31 | -$1.05M 10-K · filed 2024-02-27 | |||
| 2022-09-30 | -$563.00K 10-Q · filed 2023-11-13 | -$1.29M derived: sum of 2 quarters · filed 2023-11-13 | -$1.60M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$724.00K 10-Q · filed 2023-11-13 | -$1.03M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | -$309.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |